펩티드 합성 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품별, 용도별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Peptide Synthesis Market Growth & Trends:

The global peptide synthesis market size is expected to reach USD 1,840.6 million by 2033, registering a CAGR of 7.71% from 2025 to 2033, according to a new report by Grand View Research, Inc. Significant research and innovation targeted towards the development of peptide therapeutics is set to boost the market growth in the near future. Additionally, increasing advancements in the peptide synthesis technologies is expected to offer profitable opportunities for the companies operating in the market.

A surge in the demand for custom peptide synthesis has been observed in the recent years; several companies operating in this industry offer products and services associated with custom peptide synthesis. For instance, a UK based company namely, Almac Group offers peptide synthesis suitable for research use. Constantly growing demand and evolving market landscape for custom peptides is set to offer lucrative opportunities for the market growth. The suppliers are expanding their production capacity to suffice the increasing demand for high quality peptides across research and therapeutics areas.

Rising focus of the pharmaceutical companies towards the development of novel biologics and shifting the peptide drugs from the pipeline stage to commercial scale further strengthens the market growth. Increase in the number of research activities performed on exploring the potential of high-quality peptides and peptide libraries in the development of vaccines and biomarker discovery heavily contributes to the revenue generated by the global peptide synthesis market. Moreover, introduction of modified peptides (GMP peptides) that possess enhanced stability and pharmacokinetic properties in the market is expected to maintain the double-digit market growth throughout the forecast period.

Therapeutic peptide development has witnessed remarkable growth in the recent years, this is further driven by significant increase in the patient pool suffering from cardiovascular and metabolic diseases. This has propelled the discovery of bioactive peptides exponentially which further drives the market demand.

Peptide Synthesis Market Report Highlights:

• The reagents and consumables in the product segment dominated the peptide synthesis market with a revenue share of 47.97% in 2024. The equipment segment is expected to register a significant CAGR during the forecast period.
• The technology segment's liquid phase peptide synthesis (LPPS) dominated the peptide synthesis market with a revenue share of 44.04% in 2024. The hybrid technology segment in the peptide synthesis market is expected to register the fastest CAGR during the forecast period
• Therapeutics dominated the market with a revenue share of 70.35% in 2024. The diagnosis application segment in the peptide synthesis market is expected to register the fastest CAGR during the forecast period.
• Pharmaceutical and biotechnology companies led the market with a revenue share of 66.74% in 2024. The Contract Development & Manufacturing Organization & Contract Research Organization (CDMOs & CROs) in the end-use segment in the peptide synthesis industry are expected to register the fastest CAGR during the forecast period.
• North America peptide synthesis dominated the global market with the largest revenue share of 38.95% in 2024. The peptide synthesis market in Asia Pacific is expected to register the fastest growth, with a CAGR of 9.33% during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Technology Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segmental Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, and Scope

• 3.1. Market Lineage
  • 3.1.1. Parent Market Analysis
  • 3.1.2. Ancillary Market Analysis
• 3.2. Peptide Synthesis- Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Peptide Synthesis Market: Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Peptide Synthesis Market Product Movement Analysis, 2024 & 2033
• 4.3. Global Peptide Synthesis Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Equipment
  • 4.4.1. Global Equipment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Peptide Synthesizers
    • 4.4.2.1. Global Peptide Synthesizers Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Lyophilizers
    • 4.4.3.1. Global Lyophilizers Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Chromatography Equipment
    • 4.4.4.1. Global Chromatography Equipment Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Global Others Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.5. Reagents & Consumables
  • 4.5.1. Reagents & Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Resins
    • 4.5.2.1. Global Resins Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Amino Acids
    • 4.5.3.1. Global Amino Acids Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Coupling Reagents
    • 4.5.4.1. Global Coupling Reagents Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Dyes & Fluorescent Labeling Reagents
    • 4.5.5.1. Global Dyes & Fluorescent Labeling Reagents Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.5.6. Others
    • 4.5.6.1. Global Others Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.6. Services
  • 4.6.1.1. Global Services Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Peptide Synthesis Market: Technology Business Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Global Peptide Synthesis Market Technology Movement Analysis, 2024 & 2033
• 5.3. Global Peptide Synthesis Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 5.4. Solid Phase Peptide Synthesis (SPPS)
  • 5.4.1. Global Solid Phase Peptide Synthesis (SPPS) Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.5. Liquid Phase Peptide Synthesis (LPPS)
  • 5.5.1. Global Liquid Phase Peptide Synthesis (LPPS) Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.6. Hybrid Technology
  • 5.6.1. Global Hybrid Technology Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Peptide Synthesis Market: Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Peptide Synthesis Market Application Movement Analysis, 2024 & 2033
• 6.3. Global Peptide Synthesis Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Therapeutics
  • 6.4.1. Global Therapeutics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Cancer
    • 6.4.2.1. Global Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Metabolic
    • 6.4.3.1. Global Metabolic Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Cardiovascular Disorder
    • 6.4.4.1. Global Cardiovascular Disorder Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Respiratory
    • 6.4.5.1. Global Respiratory Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. GIT (Gastrointestinal Disorders)
    • 6.4.6.1. Global GIT (Gastrointestinal Disorders) Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Infectious Disease
    • 6.4.7.1. Global Infectious Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Pain
    • 6.4.8.1. Global Pain Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.9. Dermatology
    • 6.4.9.1. Global Dermatology Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.10. CNS
    • 6.4.10.1. Global CNS Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.11. Renal
    • 6.4.11.1. Global Renal Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4.12. Others
    • 6.4.12.1. Global Others Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.5. Diagnosis
  • 6.5.1. Global Diagnosis Peptide Synthesis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.6. Research
  • 6.6.1. Global Research Peptide Synthesis Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Peptide Synthesis Market: End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Peptide Synthesis Market End Use Movement Analysis, 2024 & 2033
• 7.3. Global Peptide Synthesis Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Pharmaceutical & Biotechnology Companies
  • 7.4.1. Global Pharmaceutical & Biotechnology Companies Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.5. CDMOs/CROs
  • 7.5.1. Global CDMOs/CROs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.6. Academic and Research Institutions
  • 7.6.1. Global Academic and Research Institutions Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Peptide Synthesis Market: Regional Estimates & Trend Analysis by Product, Technology, Application, and End Use

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2033
• 8.3. North America
  • 8.3.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Regulatory framework
    • 8.3.2.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Target disease prevalence
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Regulatory framework
    • 8.3.3.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key country dynamics
    • 8.3.4.2. Target disease prevalence
    • 8.3.4.3. Competitive scenario
    • 8.3.4.4. Regulatory framework
    • 8.3.4.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Target disease prevalence
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Regulatory framework
    • 8.4.2.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Target disease prevalence
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Regulatory framework
    • 8.4.3.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Target disease prevalence
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Regulatory framework
    • 8.4.4.5. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Target disease prevalence
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Regulatory framework
    • 8.4.5.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Target disease prevalence
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Regulatory framework
    • 8.4.6.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Target disease prevalence
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Regulatory framework
    • 8.4.7.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Target disease prevalence
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Regulatory framework
    • 8.4.8.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key country dynamics
    • 8.4.9.2. Target disease prevalence
    • 8.4.9.3. Competitive scenario
    • 8.4.9.4. Regulatory framework
    • 8.4.9.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Target disease prevalence
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Regulatory framework
    • 8.5.2.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Target disease prevalence
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Regulatory framework
    • 8.5.3.5. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Target disease prevalence
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Regulatory framework
    • 8.5.4.5. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Target disease prevalence
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Regulatory framework
    • 8.5.5.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. South Korea
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Target disease prevalence
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Regulatory framework
    • 8.5.6.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Thailand
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Target disease prevalence
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Regulatory framework
    • 8.5.7.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Target disease prevalence
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Regulatory framework
    • 8.6.2.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Target disease prevalence
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Regulatory framework
    • 8.6.3.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Target disease prevalence
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Regulatory framework
    • 8.7.2.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Target disease prevalence
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. Regulatory framework
    • 8.7.3.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Target disease prevalence
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Regulatory framework
    • 8.7.4.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Target disease prevalence
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Regulatory framework
    • 8.7.5.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Thermo Fisher Scientific Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Technology benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Merck KGaA
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Technology benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. GenScript
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Technology benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Bachem Holding AG
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Technology benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Biotage
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Technology benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Creative Diagnostics
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Technology benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. PolyPeptide Group
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Technology benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Syngene International Limited
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Technology benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Puresynth Research Chemicals Pvt Ltd.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Technology benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Lonza
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Technology benchmarking
    • 9.4.10.4. Strategic initiatives